IP Library › Granted Patent US 12,251,402
Granted Patent B2
US 12,251,402 · App. 16/750,554 · Granted Mar 18, 2025

Mesenchymal stem cells with enhanced immunosuppressive capability

Inventor: Basil M. Hantash (East Palo Alto, CA)
Assignee: Escape Therapeutics, Inc.
A61K35/28A61K9/0019C12N5/0663C12N5/0667A61K2035/124C12N2501/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,251,402
App. No.
16/750,554
Granted
Mar 18, 2025
Kind
B2
Abstract

Compositions of HLA-G+ MSC and methods of using them, including methods of transplanting compositions of HLA-G+ MSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-G+ MSC, including by treatment with DNA methylation inhibitors.

Claims (13)

1. A method of transplanting a composition comprising a population of mesenchymal stem cells (MSCs), the method comprising injecting the composition into a human recipient, wherein the population of MSCs comprises MSCs that express HLA-G (HLA-G+ MSCs), wherein the population of MSCs was contacted with a DNA methylation inhibitor prior to the injection, and wherein the HLA-G+ MSCs have (a) a methylation level at least 5% lower than MSCs that have not been contacted with the DNA methylation inhibitor and (b) HLA-G expression at least 10% higher than MSCs that have not been contacted with the DNA methylation inhibitor.

2. The method of claim 1 , wherein the HLA-G+ MSCs express HLA-G1.

3. The method of claim 1 , wherein the HLA-G+ MSCs are derived from adipose tissue or bone marrow.

4. The method of claim 1 , wherein the population of MSCs comprises at least 25% HLA-G+ MSCs.

5. The method of claim 1 , wherein the HLA-G expression in the HLA-G+ MSCs is assessable by detecting a corresponding mRNA or its transcript.

6. The method of claim 1 , wherein the HLA-G expression in the HLA-G+ MSCs is assessable by detecting a cell surface expression of HLA-G.

7. The method of claim 4 , wherein the population of MSCs comprises at least 50% HLA-G+ MSCs.

8. The method of claim 7 , wherein the population of MSCs comprises at least 90% HLA-G+ MSCs.

9. The method of claim 1 , wherein the human recipient has a disease and wherein the disease is treated or prevented by suppressing the human recipient's immune response.

10. The method of claim 9 , wherein the disease is an autoimmune disorder, an inflammatory disease, a degenerative disease, or a graft-versus-host disease.

11. The method of claim 1 , wherein the HLA-G+ MSCs express HLA-G3.

12. The method of claim 1 , wherein the HLA-G+ MSCs express HLA-G1 and HLA-G3.

13. The method of claim 12 , wherein the HLA-G+ MSCs do not express HLA-G5.

Assignments (4)
SECURITY INTEREST Recorded Apr 8, 2024
From: UNIVERXOME BIOENGINEERING, INC.
To: JUVENESCENCE LIMITED
Reel/Frame 067037/0625 →
RELEASE OF SECURITY INTEREST Recorded Mar 27, 2024
From: JUVENESCENCE LIMITED
To: AGEX THERAPEUTICS, INC.
Reel/Frame 066915/0598 →
SECURITY INTEREST Recorded Nov 10, 2023
From: AGEX THERAPEUTICS, INC.; RECYTE THERAPEUTICS, INC.; REVERSE BIOENGINEERING, INC.
To: JUVENESCENCE LIMITED
Reel/Frame 065529/0594 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2020
From: HANTASH, BASIL M.
To: ESCAPE THERAPEUTICS, INC.
Reel/Frame 051993/0153 →
Continuity (3)
Division 15250441 · Aug 29, 2016
Provisional Application 62213748 · Sep 3, 2015
Related Publication 20200155610A1 · May 21, 2020
References Cited (27)
US 7601699B2 · Eilertsen · 2009 [cited by examiner]
US 20100055785A1 · Hantash · 2010 [cited by applicant]
US 20100173414A1 · Turovets et al. · 2010 [cited by applicant]
US 20170065639A1 · Hantash · 2017 [cited by applicant]
Kim et al., New Strategies for Overcoming Limitations of Mesenchymal Stem Cell-Based Immune Modulation, International Journal of Stem Cells vol. 8, No. 1, (May 2015), pp. 54-68. [cited by examiner]
Aggarwal & Pittenger, Human Mesenchymal Stem Cells Modulate Allogenic Immune Cell Responses, Blood, 105 (4), 1815-1822, Feb. 15, 2005, (8 pages). [cited by applicant]
Beck and Trowsdale, “The Human Major Histocompatibility Complex: Lessons From the DNA Sequence,” Annual Review of Genomics and Human Genetics, vol. 1, pp. 117-137, Sep. 2000. [cited by applicant]
Cirulli, et al., “The Class I HLA Reprtoire of Pancreatic Islets Comprises the Nonclassical Class Ib Antigen HLA-G,” May 2006, Diabetes 55, 5, 1214-1222 (9 pages). [cited by applicant]
Fujimura, et al, “Neural differentiation of adipose-derived stem cells isolated from GFP transgenic mice,” Biochemical and Biophysical Research Communications, vol. 333, Issue 1, Jul. 22, 2005, pp. 116-121. [cited by applicant]
Giuliani, et al., “Long-Lasting Inhibitory Effects of Fetal Liver Mesenchymal Stem Cells on T-Lymphocyte Proliferation,” PLoS One 6(5): e19988. doi:10.1371/journal.pone.0019988, May 19, 2011, (10 pages). [cited by applicant]
Gronthos, S., et al., “Surface protein characterization of human adipose tissue-derived stromal cells,” J. Cell. Physiol., 2001, 189: 54-63. doi:10.1002/jcp.1138. [cited by applicant]
Guo, et al., “Effects of 5-aza-2′-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells,” Leukemia, 2006, vol. 20, pp. 115-121 (7 pages). [cited by applicant]
Hviid, et al., “HLA-G Polymorphisms and HLA-G Expression in Sarcoidosis,” Mar. 2006, Sarcoidosis Vase Diffuse Lung Dis., 23, 1, 30-37. [cited by applicant]
Hviid, et al., “Polymorphism in the 5′ upstream regulatory and 3′ untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression,” Jan.-Feb. 2006, Hum. Immunol. 67, (1-2), 53-62. [cited by applicant]
Ishitani, et al., “Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class Il antigens,” May 1992, Proc. Natl. Acad. Sci USA, 89, (9), 3947-3951(5 pages). [cited by applicant]
Polakova, et al., “Demethylating Agent 5-aza-2′-deoxycytidine Activates HLA-G Expression in Human Leukemia Cell Lines,” Leukemia Research, 33 (2009), pp. 518-524 (7 pages). [cited by applicant]
Pook, et al., “Characterization of an expressible nonclassical class | HLA gene,” Oct. 1991, Hum. Immunol. 32, (2), 102-109. [cited by applicant]
Rhodes and Trowsdale, “Genetics and Molecular Genetics of the MHC.” Rev. Immunogenet, 1999, 1,(1): pp. 21-31. [cited by applicant]
Robinson and Marsh, “The IMGT/HLA Sequence Database,” Reviews in Immunogenetics (2000), 2 (4), pp. 518-531. [cited by applicant]
Simmons, et al., “Isolation, Characterization, and Functional Activity of Human Marrow Stromal Progenitors in Hemopoiesis,” Prog. Clin. Biol. Res. 389, 271-280, 1994. [cited by applicant]
Sua'rez-Alvarez et al. (2010) Epigenetic Mechanisms Regulate MHC and Antigen Processing Molecules in Human Embryonic and Induced Pluripotent Stem Cells. PLoS One 5(4): e10192. doi:10.1371/journal.pone.0010192. [cited by applicant]
Takele Teklemariam, et al., “Inhibition of DNA methylation enhances HLA-G expression in human mesenchymal stem cells,” Biochemical and Biophysical Research Communications, 452, 753-759, 2014 (7 pages). [cited by applicant]
Trowsdale, “Genomic Structure and Function in the MHC,” Trends in Genetics, Apr. 1, 1993, 9 (4): pp. 117-122. [cited by applicant]
Yan, et al, “Induction of HA-G Expression in a Melanoma Cell Line OCM-1A Following the Treatment with 5-aza-2′-deoxycytidine,” Cell Research, 15 (7): pp. 523-531, Jul. 2005 (9 pages). [cited by applicant]
Yie, et al., “Progesterone regulates HLA-G gene expression through a novel progesterone response element,” Hum Reprod., Oct. 2006, 21 (10): pp. 2538-2544. [cited by applicant]
Zemmour, et al., “HLA Class | Nucleotide Sequences,” Hum. Immunol. Jul. 1991, 31 (3): pp. 195-206. [cited by applicant]
Zuk, et al., “Human Adipose Tissue Is A Source of Multipotent Stem Cells,” Molecular Biology of the Cell, vol. 13, pp. 4279-4295, Dec. 2002 (17 pages). [cited by applicant]